Definition · Plain-language
Breakthrough therapy designation
Breakthrough Therapy Designation is an FDA expedited-development programme for drugs that treat serious conditions and show, on preliminary clinical evidence, substantial improvement over existing therapy.
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
What qualifies a drug
Breakthrough Therapy Designation, created by the Food and Drug Administration Safety and Innovation Act of 2012, applies to a drug intended to treat a serious or life-threatening condition where preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available therapies on one or more clinically significant endpoints. The threshold is higher than for Fast Track because it requires preliminary clinical — not merely non-clinical — evidence of a meaningful advantage. A sponsor can request the designation, ideally early in development.
What the designation provides
A drug with Breakthrough Therapy Designation receives all the features of Fast Track, plus more intensive FDA guidance on an efficient development programme and organisational commitment involving senior agency managers. The aim is to shorten the time to a potential approval by helping the sponsor design an efficient development plan and by enabling rolling review. The designation reflects the FDA’s judgement that the early evidence is promising enough to warrant a particularly close, collaborative development effort.
How it sits among expedited programmes
Breakthrough Therapy is one of four FDA expedited programmes for serious conditions, alongside Fast Track, Accelerated Approval and Priority Review. The programmes can overlap: a breakthrough drug may also use accelerated approval or receive priority review. Each addresses a different part of the development-and-review timeline, and none changes the fundamental standard for approval — the FDA must still find the drug safe and effective before it can be marketed.
Key facts
At a glance
- Definition: Expedited programme for promising drugs for serious conditions.
- Evidence needed: Preliminary clinical evidence of substantial improvement.
- Statute: Food and Drug Administration Safety and Innovation Act (2012).
- Benefits: Fast Track features plus intensive FDA guidance and senior engagement.
- Related programmes: Fast Track, Accelerated Approval, Priority Review.
- Not an approval: Designation does not change the standard for approval.
Common misconceptions
What people often get wrong
Often heard: Breakthrough Therapy Designation means the drug is approved or proven to work.
Actually: It is an expedited-development designation based on promising preliminary evidence. The drug must still complete development and be found safe and effective through the normal approval process.
Often heard: Breakthrough Therapy and Fast Track require the same level of evidence.
Actually: Breakthrough Therapy requires preliminary clinical evidence of substantial improvement over available therapies, a higher bar than Fast Track, which can rest on non-clinical or mechanistic data addressing an unmet need.
Often heard: A breakthrough designation lowers the standard the drug must meet for approval.
Actually: The designation speeds development and review but does not change the statutory standard. The FDA must still conclude the drug is safe and effective before approval.
